Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This multimodal analgesic combination consists of the long-acting amide-type local anesthetic ropivacaine, the non-steroidal anti-inflammatory drug (NSAID) ketoprofen, and the adrenergic agonist epinephrine. It is primarily administered via periarticular injection during orthopedic procedures, such as open arthrolysis for post-traumatic elbow stiffness, to provide localized postoperative pain relief. Ropivacaine blocks nerve impulse conduction by inhibiting sodium channels, while ketoprofen provides analgesia and reduces inflammation by inhibiting cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). Epinephrine acts as a local vasoconstrictor, which serves to prolong the duration of the anesthetic effect and minimize systemic absorption and toxicity. The combination is being investigated by the Shanghai Sixth People's Hospital East Campus for its efficacy in improving postoperative recovery and joint mobility.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ropivacaine + ketoprofen + epinephrine.